Analyzing Flag Ship Acquisition (ETHZ) & Its Peers

Valuation & Earnings

This table compares Flag Ship Acquisition and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Flag Ship Acquisition	N/A	-$6.17 million	-0.16
Flag Ship Acquisition Competitors	$439.29 million	-$68.80 million	-9.23

Flag Ship Acquisition’s peers have higher revenue, but lower earnings than Flag Ship Acquisition. Flag Ship Acquisition is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

4.1% of Flag Ship Acquisition shares are held by institutional investors. Comparatively, 39.2% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 5.4% of Flag Ship Acquisition shares are held by insiders. Comparatively, 13.9% of shares of all “Pharmaceutical Preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Flag Ship Acquisition has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Comparatively, Flag Ship Acquisition’s peers have a beta of 10.48, indicating that their average share price is 948% more volatile than the S&P 500.

Profitability

This table compares Flag Ship Acquisition and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Flag Ship Acquisition	N/A	-141.25%	-80.77%
Flag Ship Acquisition Competitors	-2,594.67%	-410.78%	-44.82%

Summary

Flag Ship Acquisition peers beat Flag Ship Acquisition on 5 of the 9 factors compared.

Flag Ship Acquisition Company Profile

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.